Print
Email
Print Edition StoriesTuesday, June 1, 2010
NanoViricides announces positive results for dengue target
By Julie M. Donnelly
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
NanoViricides Inc. is reporting that early-stage cell culture studies show “significant efficacy” for the company’s anti-Dengue drug candidates. The potential drugs aim to “fool” the dengue virus into thinking it has attached to a human cell, when it has in fact attached to an artificial nanotech cell instead. The so-called nanoviricide showed an inhibition of virus infectivity by stopping the spread to new uninfected cells, company officials said. Officials at the West Haven, Conn.-based company said the drug targets could be effective against all four types of dengue.
Dengue is the most prevalent mosquito-borne viral disease in humans, with 50 to 100 million new infections each year. There is currently no approved vaccine or treatment for the dengue virus infection. Dengue hemorrhagic fever is a severe case of dengue viral infection.
Nanoviricides of West Haven, Conn., is also developing drugs against H5N1 bird flu, seasonal influenza, rabies, HIV, and hepatitis C.
The company raised $5 million in a registered shelf offering in mid-May.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
